In focus · trending topic

US FDA

8 stories · following the connections

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)

By Nasdaq OMXApr 13, 2018, 11:00 AM UTC

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)

By Nasdaq OMXApr 9, 2018, 11:00 AM UTC

Marina Biotech Announces a New Publication on Prestalia®

By Nasdaq OMXFeb 27, 2018, 3:14 PM UTC

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

By Nasdaq OMXJan 16, 2018, 1:40 PM UTC

Marina Biotech Appoints Isaac Blech to its Board of Directors

By Nasdaq OMXNov 27, 2017, 1:30 PM UTC

Melinta Therapeutics Provides Baxdela NDA Update

By Nasdaq OMXFeb 27, 2017, 1:00 PM UTC

Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA

By Nasdaq OMXJan 5, 2017, 1:01 PM UTC

Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA

By Nasdaq OMXJan 5, 2017, 1:01 PM UTC